Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology

Objective: To determine whether asymptomatic persons with Alzheimer disease (AD) neuropathologic change differ in the trajectory of their cognitive performance compared to asymptomatic persons without AD neuropathologic change. Methods: Longitudinal performance on standard neuropsychological tests was examined in participants who died within 2 years of their last cognitive assessment and who were never diagnosed with mild cognitive impairment or dementia (Clinical Dementia Rating global score of 0 at all assessments). Using cognitive and neuropathologic data collected between 2005 and 2013 from the 34 National Institute on Aging–sponsored Alzheimer's Disease Centers, cognitive trajectories were compared for persons with and without evidence of AD neuropathologic change. We evaluated rates of decline in 4 domains (episodic memory, language, attention/working memory, executive function). The significance of the differences (β) in rates of decline was tested using linear regression, adjusting for age, education, sex, and other neuropathologic lesions. Results: Participants who had low to high levels of AD neuropathologic change (n = 131) showed a greater rate of decline on the attention/working memory domain score (β = −0.11; 95% confidence interval = −0.19, −0.02; p = 0.02) when compared to 80 participants who died without evidence of AD neuropathologic change. Conclusions: Clinically normal individuals who come to autopsy with AD neuropathologic change exhibit subtle evidence of declining cognitive trajectories for attention/working memory.

[1]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[2]  R. Kessels,et al.  The Backward Span of the Corsi Block-Tapping Task and Its Association With the WAIS-III Digit Span , 2008, Assessment.

[3]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[4]  D. Knopman,et al.  Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. , 2012, Neurodegenerative disease management.

[5]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[6]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[7]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[8]  Chi-Shing Tse,et al.  Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming. , 2010, Psychology and aging.

[9]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[10]  Charles D. Smith,et al.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. , 2011, Journal of Alzheimer's disease : JAD.

[11]  D. Salmon,et al.  The Alzheimer ’ s Disease Centers ’ Uniform Data Set ( UDS ) : The Neuropsychological Test Battery , 2009 .

[12]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[13]  R. Penn,et al.  Stiff‐man syndrome treated with intrathecal baclofen , 1993, Neurology.

[14]  E. Twamley,et al.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease , 2006, Journal of the International Neuropsychological Society.

[15]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[16]  L. Schneider,et al.  Prevention trials in Alzheimer's disease: An EU-US task force report , 2011, Progress in Neurobiology.

[17]  Jeffrey N. Browndyke,et al.  Factor Structure of the National Alzheimer's Coordinating Centers Uniform Dataset Neuropsychological Battery: An Evaluation of Invariance Between and Within Groups Over Time , 2011, Alzheimer disease and associated disorders.

[18]  J. Morris,et al.  Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology , 2013, Neurology.

[19]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[20]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[21]  Joylee Wu,et al.  The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.

[22]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[23]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[24]  E. Kaplan,et al.  The Boston naming test , 2001 .

[25]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  M. Schlossberg.  The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. , 1986 .

[27]  Ira Driscoll,et al.  Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly , 2006, Annals of neurology.

[28]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[29]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[30]  Larry R Price,et al.  The joint WAIS-III and WMS-III factor structure: development and cross-validation of a six-factor model of cognitive functioning. , 2003, Psychological assessment.

[31]  S. Monsell,et al.  Choosing Alzheimer's disease prevention clinical trial populations , 2014, Neurobiology of Aging.

[32]  Nathaniel Mercaldo,et al.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.

[33]  L. Jacoby,et al.  The utility of placing recollection in opposition to familiarity in early discrimination of healthy aging and very mild dementia of the Alzheimer's type. , 2010, Neuropsychology.

[34]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[35]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[36]  D. Wechsler.  WAIS-R manual : Wechsler adult intelligence scale-revised , 1981 .

[37]  J. Morris,et al.  The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers , 2006, Alzheimer disease and associated disorders.

[38]  J. Price,et al.  Absence of cognitive impairment or decline in preclinical Alzheimer’s disease , 2001, Neurology.

[39]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[40]  H. Dodge,et al.  Terminal decline and practice effects in older adults without dementia , 2011, Neurology.

[41]  R. Wilson,et al.  Relation of neuropathology to cognition in persons without cognitive impairment , 2012, Annals of neurology.